Indonesia Herbal Remedies Firm Owners Weighing $500 Million Sale
(Bloomberg) -- The owners of PT Deltomed Laboratories are exploring a sale of the Indonesian herbal remedies manufacturer and distributor in a deal that could value the company at about $500 million, according to people with knowledge of the matter.
Indonesian buyout firm PT Saratoga Investama Sedaya and the Rahardjo family are working with an adviser on the potential divestment, said the people, who asked not to be identified as the process is private. The sellers began sounding out potential buyers last week, said the people.
The company is projecting 36% growth in revenue this year with an estimated gross margin of 65%, according to a marketing document seen by Bloomberg News.Â
Deliberations are ongoing and there is no certainty that the deal will proceed, said the people.Â
A Saratoga representative said the firm continues to find the best options for its shareholders by studying all bids and positions before making investment and divestment decisions at the right moment. A representative for Deltomed declined to comment, while the Rahardjo family couldn't be reached via Deltomed.
Founded in 1976, Deltomed's products include Antangin, used to relieve upset stomachs, and OB Herbal, a cough remedy, as well as herbal supplements sold under the Herbana brand, according to its website.Â
The company was bought in 1988 by Purwanto Rahardjo, and his eldest son Mulyo Rahardjo -- the current chief executive officer -- took over in 1992, the website shows.
©2021 Bloomberg L.P.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.